Journal article
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement
Abstract
BACKGROUND: Venous thromboembolism is a frequent complication of total hip replacement. The pentasaccharide Org31540/SR90107A, a highly selective, indirect inhibitor of activated factor X, is the first of a new class of synthetic antithrombotic agents. To determine the optimal dose for phase 3 studies, we conducted a dose-ranging study in which Org31540/SR90107A was compared with a low-molecular-weight heparin, enoxaparin, in patients …
Authors
Turpie AGG; Gallus AS; Hoek JA
Journal
The New England Journal of Medicine, Vol. 344, No. 9, pp. 619–625
Publisher
Massachusetts Medical Society
Publication Date
3 2001
DOI
10.1056/nejm200103013440901
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAged, 80 and overAnticoagulantsArthroplasty, Replacement, HipDose-Response Relationship, DrugDouble-Blind MethodEnoxaparinFemaleFibrinolytic AgentsHemorrhageHumansInjections, SubcutaneousLogistic ModelsMaleMiddle AgedOligosaccharidesPostoperative ComplicationsPulmonary EmbolismThromboembolismVenous Thrombosis